DMSO

The single most important fact about DMSO is that it does not stay where it is put, and it does not go alone. It crosses skin, and it carries dissolved solutes with it. That turns ordinary handling mistakes into routes of exposure. A contaminated glove becomes a dose. An impure compound delivers its impurities as well as itself. A container the solvent is quietly attacking contributes whatever leaches out of it. A splash that would be trivial with water is not trivial here. When a published assessment modelled the worst case for topical DMSO in a cell-therapy product, the assumption it used was 100% transdermal absorption ^[11]; that is the posture the material earns.

The corollary is that grade and purity stop being a quality question and become a safety question. Only pharmaceutical grade carries a specification for what else is in the bottle. DMSO is also strongly hygroscopic, so a container left open takes up water from the air and is no longer the solvent on the label, and it attacks many plastics and elastomers, which is why glass is the default container and why glove material should be checked against the supplier's compatibility data rather than assumed. Treat any compound of unknown identity or purity as unsuitable for dissolving in it, because DMSO removes the barrier that would otherwise have limited the mistake.

Systemic DMSO has a measured tolerability record, but it comes from supervised cell therapy rather than from casual use. Across 1173 patients given cryopreserved mesenchymal stromal cell products intravenously, the DMSO delivered was 2.5 to 30 times lower than the amount typically accepted in haematopoietic stem cell transplantation, and with adequate premedication only isolated infusion-related reactions were reported ^[11]. The field has nonetheless been working to use less of it: a systematic review and meta-analysis of controlled clinical studies found that stem cell products frozen with 5% DMSO gave better post-thaw viability of CD34 positive cells and lower rates of adverse effects in patients than 10%, with little difference in engraftment ^[10]. A review of the same question frames it as an open balance between efficacy and toxicity rather than a settled one, and as the reason the search for less cytotoxic cryoprotectants continues ^[9].

On the mucosal route there is controlled human evidence, and it is specific to one use. Intravesical instillation of a 50% solution for interstitial cystitis produced adverse drug reactions described as mild to moderate and manageable in a multicentre randomised double-blind placebo-controlled trial ^[4], and an earlier controlled crossover trial in 33 patients reported no significant side effects ^[8]. That is a clinician-administered, single-organ, supervised procedure, and it does not generalise to putting the same solution on skin.

A garlic-like odour on the breath and a similar taste in the mouth is the characteristic sign that DMSO has gone systemic by any route. It is not itself harmful, but it is a standing reminder that a topical application is not a local one. Local effects at the site are irritation, redness, burning, stinging and dryness. None of this argues against using the solvent. It argues for deciding deliberately what is dissolved in it before any of it touches skin.

DMSO was first prepared in the nineteenth century and spent most of its early life as an ordinary industrial solvent, recovered as a by-product of wood pulp processing, which is why it has always been cheap and available in bulk.

Its two careers began at almost the same time. It entered cryobiology at the very beginning of that field and has been the cryoprotectant of choice for most animal cell systems ever since, used in many thousands of cell transplants; stable storage of bone marrow and blood cells until they are needed depends on it ^[9]. In the 1960s a second use, as a topical agent and a carrier, drew an enormous amount of public enthusiasm in the United States. Clinical work was halted in 1965 after lens changes were reported in laboratory animals given high doses, and that episode is the reason DMSO never became a general-purpose approved drug despite the interest it had generated.

What survived the halt was narrow and specific. Intravesical 50% DMSO, sold as Rimso-50, was approved for interstitial cystitis ^[7], and a controlled crossover trial published in 1988 found it superior to saline placebo on both objective and subjective measures, with 53% of DMSO-treated patients markedly improved against 18% on placebo ^[8]. Separately, and much later, its role as a penetration enhancer was rebuilt on formulation science rather than on the earlier enthusiasm; three decades of data now sit behind its use in approved topical diclofenac and idoxuridine solutions ^[3].

DMSO has two reputations and they barely overlap. In laboratories it is unremarkable: the default solvent for compound stocks, the default cryoprotectant, in constant use and rarely discussed. Outside them it carries a much larger folk reputation as a suppressed topical remedy for pain and inflammation, sold in horse liniment bottles and hardware shops as readily as in pharmacies.

The evidence sorts the two apart cleanly. As a penetration enhancer it does what is claimed, supported by three decades of formulation data and by approved products built on it ^[3]. As a treatment in its own right it has one controlled indication. For interstitial cystitis and bladder pain syndrome, a systematic review and meta-analysis pooling 5 randomised trials and 9 single-arm or cohort studies across 554 patients reported improvements in symptom index, problem index and pain score after treatment ^[5]; those headline numbers are before-and-after comparisons rather than comparisons against placebo, which is a weaker design than the summary suggests. The controlled evidence is thinner and more modest: a difference of 1.8 points on the O'Leary-Sant symptom index against placebo at 12 weeks in the Japanese trial ^[4], and a Cochrane review of intravesical treatments for the same condition describing success rates across the whole category as generally modest with little consensus on the best option ^[6]. Nothing in that record supports the broader claims made for the solvent.

The practical consequence of the folk reputation is a supply problem. Material sold for veterinary or industrial use is not made to a pharmaceutical specification, and with a solvent that carries its contents through skin, the specification is the safety margin.